| Literature DB >> 15751745 |
Abstract
VIRxSYS is developing VRX-496, a lentiviral HIV-based vector encoding anti-HIV antisense envelope sequences, as a potential gene therapy for HIV infection. In July 2003, VIRxSYS undertook the initial dosing of an HIV-positive patient in a phase I/IIa trial.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15751745
Source DB: PubMed Journal: Curr Opin Investig Drugs ISSN： 1472-4472